Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :26660119
Publication Date : 2016/05/05

Combinatorial PX-866 and Raloxifene Decrease Rb Phosphorylation, Cyclin E2 Transcription, and Proliferation of MCF-7 Breast Cancer Cells.


As a potential means to reduce proliferation of breast cancer cells, a multiple-pathway approach with no effect on control cells was explored. The human interactome being constructed by the Center for Cancer Systems Biology will prove indispensable to understanding composite effects of multiple pathways, but its discovered protein-protein interactions require characterization. Accordingly, we explored the effects of regulators of one protein on downstream targets of the other protein. MCF-7 estrogen receptor-positive (ER+) breast cancer cells were treated with raloxifene to upregulate the TGF-β pathway and PX-866 to down-regulate the PI3K/Akt pathway. This resulted in highly significant downstream reduction of cell cycle proliferation in breast cancer cells with no significant proliferation reduction following similar treatment of noncancerous MCF10A breast epithelial cells. Reduced phosphorylation of p107 and substantial reduction of Rb phosphorylation were observed in response. The effects of reduced Rb and p107 phosphorylation were reflected in significant decline in E2F-1 transcriptional activity, which is dependent on pocket protein phosphorylation status. The reduced proliferation was related to decreased expression of cyclins, including E2F-1-regulated Cyclin E2, which was also in response to raloxifene and PX-866. All combinations of raloxifene and PX-866 produced significant or highly significant results for reduced MCF-7 cell proliferation, reduced Cyclin E2 transcription, and reduced Rb phosphorylation. These studies demonstrated that uncontrolled proliferation of ER+ breast cancer cells can be significantly reduced by combinational targeting of two relevant pathways. J. Cell. Biochem. 117: 1688-1696, 2016. © 2015 Wiley Periodicals, Inc.

Authors : Peek Gregory W , Tollefsbol Trygve O ,

Related products :

Catalog number Product name Quantity
orb60251 Evista A selective estrogen receptor modulator(SERM). raloxifene inhibited the proliferation of the human breast cancer cell line, MCF-7, with IC50=0.2 nM For research use only. 100 mg
PR-763 BRCA1His Breast per Ovary Cancer Gene 1 Product, Tumor Suppressor Protein and Transcription Factor human, recombinant, Sf9 insect cells 2
Breast - BRC1502 Breast cancer array, non_overlapping with BRC1501, consists of duplicated 70 cases covering all the common types of breast cancer and 5 cases of normal and other non_malignant breast tissues. 1.1mm
Breast - BRC1501 Breast cancer array consists of duplicated 70 cases covering all the common types of breast cancer and 5 cases of normal and other non_malignant breast tissues. 1.1mm
Breast - BRC961 Breast cancer array consists of duplicated 36 cases covering all the common types of breast cancer and 12 cases of normal and other non_malignant breast tissues. 1.5mm
Breast - BRC481 Breast cancer array, 16 cases of breast cancer, each in duplicates, paired with corresponding uninvolved tissues from the same patients 2mm
Breast - BRC711 Breast cancer array, 71 cases of breast cancer, together with BRC491 forming the breast cancer array set. 1.1mm
Breast - BRC491 Breast cancer array, 49 cases of breast cancer, together with BRC711 forming the breast cancer array set. 1.7mm
31-070 HSP90AB1 is an isoform of the hsp90 family. It is expressed in cancer cells, but not associated with cell proliferation. 0.1 mg
30-121 C21orf33 inhibits both estrogen- and heregulin-beta1-stimulated growth of breast cancer cells, and further suggests that growth inhibition induced in these cells by all-trans retinoic acid occurs via 0.1 mg
BC08014 Breast cancer (multiple types of breast cancer) tissue array, 63 cases_63 cores, replaced by BR8018
BC08014 Breast cancer (multiple types of breast cancer) tissue array, 63 cases_63 cores, replaced by BR8018; ihc Anti-Actin confirmed
1240 Breast cancer, matched metastatic carcinoma and cancer adjacent normal breast tissue array, including TNM, clinical stage and pathology grade, 48 cases_ 96 cores,
9-80027 Human Cancer PrimaCell™4: Breast Tumor Cells, primary cell culture 1 x 100 ml
2-96027 Human Cancer PrimaCell™4: Breast Tumor Cells, primary cell culture Kit
9-46027 Human Cancer PrimaCell™4: Breast Tumor Cells, primary cell culture 5 x 100 ml
9-47027 Human Cancer PrimaCell™4: Breast Tumor Cells, primary cell culture set
4-28027 Human Cancer PrimaCell™4: Breast Tumor Cells, primary cell culture Kit
AP-305-B Breast Cancer Cells (a-peptide 18), Peptide Aptamer, Biotinylated Species Reactivity: 1 mg Product tipe: Peptide Aptamers
AP-305-U Breast Cancer Cells (a-peptide 18), Peptide Aptamer, Unlabelled Species Reactivity: 5 mg Product tipe: Peptide Aptamers
AP-305-F Breast Cancer Cells (a-peptide 18), Peptide Aptamer, FITC labelled 1 mg
AP-305-F Breast Cancer Cells (a-peptide 18), Peptide Aptamer, FITC labelled Species Reactivity: 1 mg Product tipe: Peptide Aptamers
PR-765 pRB Retinoblastoma Protein, Tumor Suppressor Protein, Transcription Factor and Proliferation Factorhuman, recombinant, Sf9 insect cells 5
P482150 7-[4-(2-Piperidinyl)ethoxy]benzoyl Raloxifene (Raloxifene Impurity) C42H44N2O6S CAS: 1159977-58-8 1 mg
AP-305-B Breast Cancer Cells (a-peptide 18), Peptide Aptamer, Biotinylated 1 mg


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur